ReviewJournal of the American Society of Nephrology : JASN2026
Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.
Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. Recent discoveries identifying circulating antiangiogenic factors-particularly soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin-as key mediators of the maternal syndrome have transformed understanding of its pathogenesis. These insights have led to the development of molecular diagnostics, such as sFlt-1, placental growth factor, and their ratio, now integrated into clinical practice for improved prediction, diagnosis, and management. The serum sFlt-1/placental growth factor is particularly useful for nephrologists for early detection of superimposed preeclampsia in pregnant women with CKD. Emerging therapeutic strategies-including targeted apheresis, recombinant ligands, RNA-based interventions, and small-molecule modulators-offer promise for disease modification. Preeclampsia also confers long-term cardiovascular and kidney risks for mothers and adverse pulmonary outcomes for offspring, underscoring its lifelong effect. Progress in preeclampsia care will depend on sustained scientific innovation and the responsible inclusion of pregnant women in clinical trials to ensure that future diagnostics and therapies are both safe and effective for both mother and baby.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.